Please use this identifier to cite or link to this item:
Title: Sentinel lymph node biopsy versus observation in thick melanoma: A multicenter propensity score matching study.
Authors: Boada, Aram
Tejera-Vaquerizo, Antonio
Ribero, Simone
Puig, Susana
Moreno-Ramírez, David
Descalzo-Gallego, Miguel A
Fierro, María T
Quaglino, Pietro
Carrera, Cristina
Malvehy, Josep
Vidal-Sicart, Sergi
Bennássar, Antoni
Rull, Ramón
Alos, Llucìa
Requena, Celia
Bolumar, Isidro
Traves, Víctor
Pla, Ángel
Fernández-Figueras, María T
Ferrándiz, Carlos
Pascual, Iciar
Manzano, José L
Sánchez-Lucas, Marina
Giménez-Xavier, Pol
Ferrandiz, Lara
Nagore, Eduardo
Keywords: melanoma;prognosis;propensity score;sentinel lymph node biopsy
metadata.dc.subject.mesh: Aged
Lymph Nodes
Lymphatic Metastasis
Middle Aged
Propensity Score
Retrospective Studies
Sentinel Lymph Node Biopsy
Skin Neoplasms
Survival Analysis
Issue Date: 13-Oct-2017
Abstract: The clinical value of sentinel lymph node (SLN) biopsy in thick melanoma patients (Breslow >4 mm) has not been sufficiently studied. The aim of the study is to evaluate whether SLN biopsy increases survival in patients with thick cutaneous melanoma, and, as a secondary objective, to investigate correlations between survival and lymph node status. We included 1,211 consecutive patients with thick melanomas (>4 mm) registered in the participating hospitals' melanoma databases between 1997 and 2015. Median follow-up was 40 months. Of these patients, 752 were matched into pairs by propensity scores based on sex, age, tumor location, histologic features of melanoma, year of diagnosis, hospital and adjuvant interferon therapy. The SLN biopsy vs. observation was associated with better DFS [adjusted hazard ratio (AHR), 0.74; 95% confidence interval (CI) 0.61-0.90); p = 0.002] and OS (AHR, 0.75; 95% CI, 0.60-0.94; p = 0.013) but not MSS (AHR, 0.84; 95% CI, 0.65-1.08; p = 0.165). SLN-negative patients had better 5- and 10-year MSS compared with SLN-positive patients (65.4 vs. 51.9% and 48.3 vs. 38.8%; p = 0.01, respectively). As a conclusion, SLN biopsy was associated with better DFS but not MSS in thick melanoma patients after adjustment for classic prognostic factors. SLN biopsy is useful for stratifying these patients into different prognostic groups.
metadata.dc.identifier.doi: 10.1002/ijc.31078
Appears in Collections:Producción 2020

Files in This Item:
There are no files associated with this item.

This item is protected by original copyright

Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.